Dwivedi Samarth, Chavan Atharva, Paul Atish T
Natural Product Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (Pilani Campus), Pilani 333031, Rajasthan, India.
Natural Product Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (Pilani Campus), Pilani 333031, Rajasthan, India.
Drug Discov Today. 2023 Oct;28(10):103754. doi: 10.1016/j.drudis.2023.103754. Epub 2023 Aug 28.
Diabetic nephropathy (DN) is a dreadful complication of diabetes that affects ∼50% of diabetics and is a leading cause of end-stage renal disease (ESRD). Studies have linked aberrant expression of lysine methyltransferases (KMTs) to the onset and progression of DN. SET7 is a KMT that methylates specific lysine residues of the histone and nonhistone proteins. It plays an important role in the transforming growth factor-β (TGF-β)-induced upregulation of extracellular matrix (ECM)-associated genes that are responsible for the inflammatory cascade observed in DN. Inhibiting SET7 has potential to attenuate renal disorders in animal studies. This review will focus on the role of SET7 in DN and its potential as a therapeutic target to combat DN.
糖尿病肾病（DN）是糖尿病一种可怕的并发症，影响约50%的糖尿病患者，是终末期肾病（ESRD）的主要原因。研究已将赖氨酸甲基转移酶（KMT）的异常表达与DN的发生和进展联系起来。SET7是一种KMT，可使组蛋白和非组蛋白蛋白质的特定赖氨酸残基甲基化。它在转化生长因子-β（TGF-β）诱导的细胞外基质（ECM）相关基因上调中起重要作用，这些基因与DN中观察到的炎症级联反应有关。在动物研究中，抑制SET7有可能减轻肾脏疾病。本综述将聚焦于SET7在DN中的作用及其作为对抗DN治疗靶点的潜力。
